Search Medical Condition
Please enter condition
Please choose location from dropdown

DeBary, Florida Clinical Trials

A listing of DeBary, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (116) clinical trials

Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

This study will be conducted in two phases. The Phase 1 portion of the study will employ a sequential group dose-escalation design to determine the dose-limiting toxicity (DLT) and recommended Phase 2 dose (RP2D) of birinapant administered in combination with 200 mg pembrolizumab, both administered as a 30-minute intravenous (IV) ...

Phase

4.22 miles

Learn More »

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.

Phase

4.22 miles

Learn More »

A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

This is a multicenter, Phase 3, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of etrolizumab compared with placebo during induction and maintenance treatment of moderate to severely active CD in participants who are refractory or intolerant to corticosteroids (CS), immunosuppressants (IS), or anti-tumor necrosis factors (anti-TNFs) or have ...

Phase

4.22 miles

Learn More »

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

This is a Phase III, open-label, randomized, controlled, international study. Approximately 360 patients < 82 years of age with MDS classified as RAEB-1, RAEB-2, or RAEB-t who received AZA or DAC for 9 months and/or 9 cycles over 12 months and had their last dose of AZA or DAC within ...

Phase

4.22 miles

Learn More »

ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer

This is an international, multi-center, open-label, randomized, Phase III study in patients with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. The primary objective of this study is to compare the efficacy of sacituzumab govitecan to the treatment of physician's ...

Phase

4.22 miles

Learn More »

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen

This is a two-part, multi-center, prospective, randomized, placebo-controlled, parallel-group study, in which adolescent subjects with schizophrenia will be enrolled. Overall, eligible subjects will be randomized in a pre-defined 1:1 ratio to NaBen or placebo. This study will be conducted in two parts: In Part 1 (Phase IIb) of the study, ...

Phase

4.22 miles

Learn More »

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

The purpose of this study is to determine if ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).

Phase

4.22 miles

Learn More »

Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer

OBJECTIVES: - To develop a web-based Breast Cancer Collaborative Registry (BCCR) as a repository for socio-demographic, environmental, clinical history, family history, and biospecimen data collected at the National Comprehensive Cancer Network (NCCN) centers for participants with a personal history of breast cancer and/or characteristics of hereditary breast cancer. - To ...

Phase N/A

4.22 miles

Learn More »

A phase III Efficacy and Safety of 3 week fixed dose asenapin treatment in pediatric acute manic or mixed episodes associated with Bipolar 1 Disorder in adolescents. Patient Inclustion Criteria: The subject is aged between 10 and 17 years, inclusive. The subject suffers from bipolar 1 disorder.

Phase

4.22 miles

Learn More »

An 8 week, placebo-controlled, double-blind, randomized, fixed-dose efficacy and safety study of asenapine in adolescent subjects with schizophrenia. Patient Inclustion Criteria: The subject is aged between 10 and 17 years, inclusive. The subject suffers from schizophrenia.

Phase

4.22 miles

Learn More »